SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors weigh the potential for a transformative buyout ahead of a long-awaited trial event, while the community remains sharply divided between bulls anticipating a massive premium and bears expressing skepticism over trial timelines and asset efficacy.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as traders closely monitor escalating geopolitical tensions in the Strait of Hormuz and the status of US-Iran negotiations, which remain a primary driver of market sentiment. The community is actively debating the sustainability of the current AI-led market rally, with many investors weighing the risks of high capital expenditures against potential economic instability and rising interest rates.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing extreme volatility and a parabolic rally, fueled by intense investor enthusiasm surrounding AI-driven memory storage demands and persistent supply chain bottlenecks. The stock has become a primary focal point for momentum traders, sparking heated debates between bulls banking on a structural supercycle and bears warning of a speculative bubble due to its rapid, historic price appreciation.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position for imminent long-term efficacy results from the VELA Phase 3 program, which many view as a critical rerating catalyst. With institutional interest rising and active discussions focused on the potential for superior clinical data compared to current market leaders, participants are closely monitoring the upcoming investor conference for possible M&A discussions or pipeline updates.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant momentum as investors digest unconfirmed reports of a domestic chip manufacturing partnership with Apple, further fueled by government-backed foundry initiatives. The stock remains a focal point for community debate, with traders weighing a potential multi-year turnaround narrative against concerns that current price levels may already be extended following a period of rapid appreciation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing strong investor engagement driven by its structural positioning in the AI data center market and excitement surrounding upcoming product catalysts. The community is actively discussing the stock's role in the broader semiconductor sector rotation, focusing on its ability to capture long-term demand for compute power amidst shifting macroeconomic conditions.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently trending as the community scrutinizes the company's shift toward high-volume commercial scaling and its strategic expansion into smart glasses, drones, and wearable markets. Investors are actively debating the viability of the company's manufacturing throughput and the recent shift in battery qualification timelines, while monitoring the broader implications of its expanding supply chain partnerships across Asia.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing significant market interest as investors pivot toward its long-term potential in edge AI, automotive, and data center infrastructure, moving beyond its traditional smartphone focus. The community is actively discussing upcoming catalysts like investor day, potential hyperscaler partnerships, and the stock's relative value compared to other high-flying semiconductor peers.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending as investors react to a significant partnership with Midjourney to integrate its ultrasound-on-chip technology into a new AI-powered full-body scanner. While the community is actively debating the stock's long-term potential as a semiconductor play versus immediate dilution risks and a 'sell-the-news' pullback, the stock has seen heightened volume and volatility as bulls look for a breakthrough of key resistance levels.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is seeing renewed momentum as investors bet on the companys zinc-based battery technology to solve critical grid-balancing and data center power bottlenecks during the AI infrastructure boom. Community sentiment remains split between excitement over a series of new purchase orders and capacity expansion projects, and long-term concerns regarding potential share dilution and historical operational hurdles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harvard Bioscience Q1 2026 Earnings Call Transcript

Harvard Bioscience (NASDAQ:HBIO) Director William Snider Purchases 8,475 Shares

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) Director William Snider purchased 8,475 shares of the stock in a transaction dated Tuesday, March 17th. The shares were bought at an average...

Harvard Bioscience (NASDAQ:HBIO) Director Stephen Denelsky Purchases 10,000 Shares

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) Director Stephen Denelsky acquired 10,000 shares of Harvard Bioscience stock in a transaction that occurred on Tuesday, March 17th. The shares...

Harvard Bioscience (NASDAQ:HBIO) Director William Snider Acquires 12,525 Shares

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) Director William Snider purchased 12,525 shares of the stock in a transaction dated Monday, March 16th. The stock was acquired at an average...

Insider Buying: Harvard Bioscience (NASDAQ:HBIO) Director Purchases 8,475 Shares of Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) Director William Snider bought 8,475 shares of the stock in a transaction on Tuesday, March 17th. The stock was purchased at an average price...

John Duke Purchases 5,000 Shares of Harvard Bioscience (NASDAQ:HBIO) Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) CEO John Duke bought 5,000 shares of the firm's stock in a transaction on Monday, March 16th. The shares were acquired at an average price of...

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, China, United Kingdom, and Rest of the World. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.

Harvard Bioscience Inc.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.21	--	--	N/A
Q1 '26	-$0.62	-$0.33	46.77%	BEAT
Q4 '25	$0.04	$0.00	-100.00%	MISSED
Q3 '25	$0.00	$0.00	-100.00%	MISSED
Q2 '25	-$0.03	-$0.01	60.00%	BEAT

HBIOHarvard Bioscience Inc.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest HBIO News